Nicola Gökbuget

Goethe University Frankfurt — Germany

Medicine · Health Sciences

71h-index23.8kcitations333works8.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Lymphoblastic Leukemia research(266), Chronic Myeloid Leukemia Treatments(145), Chronic Lymphocytic Leukemia Research(87), Acute Myeloid Leukemia Research(79), Lymphoma Diagnosis and Treatment(54)

Publications331 total

ALLCatchR, a machine-learning classifier identifies now 20 T-ALL subtypes across cohorts and age groups
2026Open Access
Reduced intensity conditioning with 8 Gy total body irradiation in adult patients with acute lymphoblastic leukemia
Bone Marrow Transplantation·2025Open Access
Osteonecrosis risk in adult ALL: Insights from real-world clinical laboratory data in eighty-seven patients treated with peg-asparaginase
Blood·2025
Outcome of adult B-precursor acute lymphoblastic leukemia (ALL) treated with blinatumomab in addition to chemotherapy independent of MRD: First results from the national GMALL registry
Blood·2025Open Access
Baseline T-cell fitness and subtype-specific CD19 loss as drivers of blinatumomab resistance in B-ALL
Blood·2025Open Access
ALL-562: Outcomes in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin Stratified by Cumulative Dose
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: ALL-562 Outcomes in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin Stratified by Cumulative Dose
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: ALL-597 Outcomes in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin Stratified by Body Mass Index
Clinical Lymphoma Myeloma & Leukemia·2025
ALL-597: Outcomes in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin Stratified by Body Mass Index
Clinical Lymphoma Myeloma & Leukemia·2025
Intra-subtype heterogeneity shapes treatment response in <i>KMT2A</i> -rearranged ALL across all age groups
2025· 1 citedOpen Access
Outcomes in patients with B-cell precursor acute lymphoblastic leukemia receiving inotuzumab ozogamicin stratified by body mass index.
Journal of Clinical Oncology·2025· 1 cited
The role of blinatumomab in adult acute B lymphoblastic leukaemia
British Journal of Haematology·2025· 1 citedOpen Access
NGS-based IG/TR gene rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation
Blood·2025· 3 citedOpen Access
Inotuzumab Ozogamicin as First-Line Therapy in Acute Lymphoblastic Leukemia
Clinical Lymphoma Myeloma & Leukemia·2025· 4 cited
Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia
The Lancet Haematology·2024· 2 cited
Next‐generation sequencing and high DNA input identify previously missed measurable residual disease in peripheral blood of B‐cell precursor acute lymphoblastic leukaemia
British Journal of Haematology·2024· 2 citedOpen Access
How I treat older patients with Ph/BCR-ABL–negative acute lymphoblastic leukemia
Blood·2024· 5 cited
Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols
Leukemia·2024· 11 citedOpen Access
Plasmapheresis effectively abrogates severe liver toxicity of pegaspargase in a patient with acute lymphoblastic leukemia
Annals of Hematology·2024· 2 citedOpen Access
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL
Blood Advances·2024· 13 citedOpen Access
page 1 of 17Next →

Frequent Co-authors

Dieter Hoelzer(30), Monika Brüggemann(18), Stefan Schwartz(12), Michael Kneba(11), Eckhard Thiel(11), Thomas Burmeister(10), Matthias Stelljes(9), Thorsten Raff(9), D. Hoelzer(9), Max S. Topp(8), Andreas Viardot(8), Oliver G. Ottmann(8), Claudia D. Baldus(8), Adele K. Fielding(7), Gerhard Zugmaier(7), Ralf C. Bargou(7), Heinz‐August Horst(7), Dirk Nagorsen(6), Svenja Neumann(6), Albrecht Reichle(6)